A case of acute generalized exanthematous pustulosis caused by exposure to Atovaquone/proguanil

Arsuaga, Marta; Trigo, Elena; Barreiro, Pablo; Calle, Fernando; Tarin, Eloy José; Loli-Ausejo, David; Díaz, M. A. Martín

doi:10.1093/jtm/taaa034

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other antimicrobials implicated in the pathogenesis of AGEP include antifungals, namely fluconazole, miconazole oral gel, nystatin, and terbinafine; antivirals, including acyclovir, favipiravir, remdesivir, and ritonavir; antiparasitic drugs, namely benznidazole and praziquantel; and other antimalarials, including atovaquone/proguanil [ 58 , 70 – 84 ].…”

Section: Pathogenesismentioning

confidence: 99%

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

et al. 2023

View full text Add to dashboard Cite

Acute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous adverse reaction mainly attributed to drugs, although other triggers, including infections, vaccinations, ingestion of various substances, and spider bites, have also been described. AGEP is characterized by the development of edema and erythema followed by the eruption of multiple punctate, non-follicular, sterile pustules and subsequent desquamation. AGEP typically has a rapid onset and prompt resolution within a few weeks. The differential diagnoses for AGEP are broad and include infectious, inflammatory, and drug-induced etiologies. Diagnosis of AGEP depends on both clinical and histologic criteria, as cases of overlap with other disease processes have been reported. Management includes removal of the offending drug or treatment of the underlying cause, if necessary, and supportive care, as AGEP is a self-limited disease. This review aims to provide an overview and update on the epidemiology, pathogenesis, reported precipitating factors, differentials, diagnosis, and management of AGEP.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

et al. 2023

View full text Add to dashboard Cite

show abstract

Atovaquone/proguanil

2021

Reactions Weekly

View full text Add to dashboard Cite

Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients

Vallejo-Yagüe

Torre

Mohamad

et al. 2022

JCM

View full text Add to dashboard Cite

Acute generalized exanthematous pustulosis (AGEP) is a rare skin reaction, commonly caused by drugs. Available evidence mostly relies on small studies or case reports. We collected published AGEP case reports and, subsequently, described the patient characteristics, suspect and concomitant drugs, time to onset, disease management, and clinical prognosis. This study included 297 AGEP patients (64.3% women) obtained from 250 published case reports or case series with individual patient data. AGEP affected patients of all ages, but the majority of patients (88.2%) were ≥25 years old. The most frequently reported suspect drugs were anti-infectives for systemic use (36.5%), particularly antibacterials for systemic use (31.0%), and especially beta-lactam antibacterials (18.3%) and macrolides (4.3%). Other frequent suspect drugs were antineoplastics (12.2%), and anti-inflammatory/anti-rheumatic products (5.2%) plus hydroxychloroquine (12.8%). Mean time to onset was 9.1 days (standard deviation SD 13.94). Some patients developed fever (64.3%) and systemic involvement (18.9%), and most patients (76.4%) received pharmacological treatment for AGEP. Seven patients died, although five of them were already critically ill prior to AGEP. In conclusion, antibiotics remain the most common suspected cause of AGEP. While case mortality rate may be up to 2.5%, disentangling the role of AGEP on the fatal outcome from the role of the preexisting health conditions remains challenging.

show abstract

A case of acute generalized exanthematous pustulosis caused by exposure to Atovaquone/proguanil

Cited by 3 publications

References 4 publications

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management

Atovaquone/proguanil

Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients

Contact Info

Product

Resources

About